iTeos Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Gosselies Belgium (2011)
Status: Acquired by GlaxoSmithKline (2021)

Organization Overview

First Clinical Trial
2019
NCT05553808
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

iTeos Belgium SA | iTeos Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 13